Free Trial

MBX Biosciences (MBX) Stock Price, News & Analysis

MBX Biosciences logo
$12.62 +0.03 (+0.20%)
As of 09:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MBX Biosciences Stock (NYSE:MBX)

Key Stats

Today's Range
$12.24
$12.74
50-Day Range
$5.79
$12.60
52-Week Range
$4.81
$27.50
Volume
212,687 shs
Average Volume
250,449 shs
Market Capitalization
$421.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50
Consensus Rating
Buy

Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

MBX Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

MBX MarketRank™: 

MBX Biosciences scored higher than 62% of companies evaluated by MarketBeat, and ranked 475th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MBX Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about MBX Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for MBX Biosciences are expected to grow in the coming year, from ($13.25) to ($2.30) per share.

  • Short Interest

    There is no current short interest data available for MBX.
  • Dividend Yield

    MBX Biosciences does not currently pay a dividend.

  • Dividend Growth

    MBX Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MBX.
  • News Sentiment

    MBX Biosciences has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for MBX Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for MBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MBX Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $45,312.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    52.19% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about MBX Biosciences' insider trading history.
Receive MBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter.

MBX Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
Ascendis Pharma initiated with an Outperform at RBC Capital
See More Headlines

MBX Stock Analysis - Frequently Asked Questions

MBX Biosciences' stock was trading at $18.43 at the start of the year. Since then, MBX stock has decreased by 32.1% and is now trading at $12.52.
View the best growth stocks for 2025 here
.

MBX Biosciences, Inc. (NYSE:MBX) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($2.78) earnings per share for the quarter, missing analysts' consensus estimates of ($2.72) by $0.06.

MBX Biosciences (MBX) raised $163 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 10,200,000 shares at $16.00 per share.

Top institutional shareholders of MBX Biosciences include Wellington Management Group LLP (7.89%), Driehaus Capital Management LLC (4.72%), MPM Bioimpact LLC (3.39%) and Woodline Partners LP (2.63%). Insiders that own company stock include Life Sciences X LP Frazier, Edward T Mathers, P Kent Hawryluk and Ora H Pescovitz.
View institutional ownership trends
.

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
11/07/2024
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:MBX
Previous Symbol
NYSE:MBX
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.50
High Stock Price Target
$44.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+199.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$418.47 million
Optionable
N/A
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:MBX) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners